Although we found that SV2A did not reside within 5 kb of the CpG sites comprising the darkgreen module, our study does reinforce that methylomic alterations in synaptic genes are observed in AD+P, so this treatment could still be explored for its therapeutic efficacy in psychosis in AD. Here, SV2A is linked to Alzheimer disease.